Citadel Advisors - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 63 filers reported holding BRIDGEBIO PHARMA INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 1.3%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$26,991,277
+24.8%
1,023,560
-18.6%
0.01%
+50.0%
Q2 2023$21,632,612
+62.4%
1,257,710
+56.5%
0.00%
+33.3%
Q1 2023$13,322,561
-40.8%
803,532
-72.8%
0.00%
-40.0%
Q4 2022$22,497,958
+20.1%
2,952,488
+56.6%
0.01%
+25.0%
Q3 2022$18,737,000
+118.8%
1,885,012
+99.9%
0.00%
+100.0%
Q2 2022$8,562,000
+52.8%
942,994
+70.8%
0.00%
+100.0%
Q1 2022$5,604,000
-58.9%
552,062
-32.5%
0.00%
-66.7%
Q4 2021$13,642,000
-39.2%
817,900
+71.0%
0.00%
-25.0%
Q3 2021$22,420,000
-28.6%
478,348
-7.2%
0.00%
-42.9%
Q2 2021$31,417,000
+75.2%
515,378
+77.0%
0.01%
+75.0%
Q1 2021$17,936,000
-15.0%
291,185
-1.8%
0.00%
-20.0%
Q4 2020$21,090,000
+337.4%
296,583
+130.8%
0.01%
+400.0%
Q3 2020$4,822,000
+117.2%
128,518
+88.8%
0.00%0.0%
Q2 2020$2,220,000
+15.7%
68,084
+2.9%
0.00%
Q1 2020$1,919,000
+219.3%
66,168
+197.0%
0.00%
Q2 2019$601,00022,2810.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q2 2019
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$55,099,00039.31%
M28 Capital Management LP 466,200$4,233,0004.74%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$282,034,0003.75%
Octagon Capital Advisors LP 933,743$8,478,0002.26%
VIKING GLOBAL INVESTORS LP 26,620,991$241,719,0001.11%
HHLR ADVISORS, LTD. 5,362,014$48,687,0001.04%
Cormorant Asset Management, LP 1,469,179$13,340,0001.01%
Knott David M Jr 213,206$1,936,0000.81%
Fernwood Investment Management, LLC 183,900$1,670,0000.72%
HighVista Strategies LLC 105,942$962,0000.58%
View complete list of BRIDGEBIO PHARMA INC shareholders